Resource Summary Report

Generated by FDI Lab - SciCrunch.org on Apr 16, 2025

Androgen Receptor (D6F11) XP Rabbit mAb

RRID:AB_10691711
Type: Antibody

Proper Citation

(Cell Signaling Technology Cat# 5153, RRID:AB_10691711)

Antibody Information

URL: http://antibodyregistry.org/AB_10691711

Proper Citation: (Cell Signaling Technology Cat# 5153, RRID:AB_10691711)

Target Antigen: Androgen Receptor (D6F11) XP Rabbit mAb

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W, IP, IHC-P, IF-IC, F, ChIP, ChIP-seq. Consolidation on 10/2018: AB_10691711, AB_10692774.

Antibody Name: Androgen Receptor (D6F11) XP Rabbit mAb

Description: This monoclonal targets Androgen Receptor (D6F11) XP Rabbit mAb

Target Organism: human

Antibody ID: AB_10691711

Vendor: Cell Signaling Technology

Catalog Number: 5153

Record Creation Time: 20231110T070233+0000

Record Last Update: 20241115T011637+0000

Ratings and Alerts

No rating or validation information has been found for Androgen Receptor (D6F11) XP Rabbit mAb.

No alerts have been found for Androgen Receptor (D6F11) XP Rabbit mAb.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 41 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Guo J, et al. (2024) TNIK drives castration-resistant prostate cancer via phosphorylating EGFR. iScience, 27(1), 108713.

Pu T, et al. (2024) Stromal-derived MAOB promotes prostate cancer growth and progression. Science advances, 10(6), eadi4935.

Manzar N, et al. (2024) An integrative proteomics approach identifies tyrosine kinase KIT as a therapeutic target for SPINK1-positive prostate cancer. iScience, 27(3), 108794.

Andolfi C, et al. (2024) MED12 and CDK8/19 Modulate Androgen Receptor Activity and Enzalutamide Response in Prostate Cancer. Endocrinology, 165(10).

Garcia Castro DR, et al. (2023) Increased SIRT3 combined with PARP inhibition rescues motor function of SBMA mice. iScience, 26(8), 107375.

Li X, et al. (2023) Loss of SYNCRIP unleashes APOBEC-driven mutagenesis, tumor heterogeneity, and AR-targeted therapy resistance in prostate cancer. Cancer cell, 41(8), 1427.

Backe SJ, et al. (2023) Activation of autophagy depends on Atg1/Ulk1-mediated phosphorylation and inhibition of the Hsp90 chaperone machinery. Cell reports, 42(7), 112807.

Patterson JC, et al. (2023) Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling. Cancer research, 83(2), 219.

Fischer JR, et al. (2023) Multiplex imaging of breast cancer lymph node metastases identifies prognostic single-cell populations independent of clinical classifiers. Cell reports. Medicine, 4(3), 100977.

Jovanovi? B, et al. (2023) Heterogeneity and transcriptional drivers of triple-negative breast

cancer. Cell reports, 42(12), 113564.

Boston AM, et al. (2023) Discordant interactions between YAP1 and polycomb group protein SCML2 determine cell fate. iScience, 26(10), 107964.

Li X, et al. (2023) Spermine is a natural suppressor of AR signaling in castration-resistant prostate cancer. Cell reports, 42(7), 112798.

Zhang Y, et al. (2023) Single-cell RNA sequencing reveals that HSD17B2 in cancer-associated fibroblasts promotes the development and progression of castration-resistant prostate cancer. Cancer letters, 566, 216244.

Liu J, et al. (2023) A kinome-wide CRISPR screen identifies CK1? as a target to overcome enzalutamide resistance of prostate cancer. Cell reports. Medicine, 4(4), 101015.

Khatiwada P, et al. (2023) The Transmembrane Protein TM4SF3 Interacts With AR and AR-V7 and is Recruited to AR Target Genes. Endocrinology, 164(5).

Sperger JM, et al. (2023) Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 29(12), 2324.

Tabrizian N, et al. (2023) ASCL1 is activated downstream of the ROR2/CREB signaling pathway to support lineage plasticity in prostate cancer. Cell reports, 42(8), 112937.

Liang D, et al. (2023) Ferroptosis surveillance independent of GPX4 and differentially regulated by sex hormones. Cell, 186(13), 2748.

Crowell PD, et al. (2023) MYC is a regulator of androgen receptor inhibition-induced metabolic requirements in prostate cancer. Cell reports, 42(10), 113221.

Khan MA, et al. (2023) MYB exhibits racially disparate expression, clinicopathologic association, and predictive potential for biochemical recurrence in prostate cancer. iScience, 26(12), 108487.